1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Meucci, R.D.; Fassa, A.G.; Faria, N.M. Prevalence of chronic low back pain: Systematic review. Rev. Saude Publica 2015, 49, 1.
[CrossRef] [PubMed]
Andersson, G.B. Epidemiological features of chronic low-back pain. Lancet 1999, 354, 581–585. [CrossRef] [PubMed]
Yurube, T.; Takeoka, Y.; Kanda, Y.; Kuroda, R.; Kakutani, K. Intervertebral disc cell fate during aging and degeneration: Apoptosis,
senescence, and autophagy. N. Am. Spine Soc. J. 2023, 14, 100210. [CrossRef] [PubMed]
Oegema, T.R., Jr. Biochemistry of the intervertebral disc. Clin. Sports Med. 1993, 12, 419–439. [CrossRef]
Lotz, J.C.; Hsieh, A.H.; Walsh, A.L.; Palmer, E.I.; Chin, J.R. Mechanobiology of the intervertebral disc. Biochem. Soc. Trans. 2002,
30, 853–858. [CrossRef]
Fontana, G.; See, E.; Pandit, A. Current trends in biologics delivery to restore intervertebral disc anabolism. Adv. Drug Deliv. Rev.
2015, 84, 146–158. [CrossRef]
Molinos, M.; Almeida, C.R.; Caldeira, J.; Cunha, C.; Goncalves, R.M.; Barbosa, M.A. Inflammation in intervertebral disc
degeneration and regeneration. J. R. Soc. Interface 2015, 12, 20150429. [CrossRef]
Miyazaki, K.; Miyazaki, S.; Yurube, T.; Takeoka, Y.; Kanda, Y.; Zhang, Z.; Kakiuchi, Y.; Tsujimoto, R.; Ohnishi, H.; Matsuo, T.; et al.
Protective Effects of Growth Differentiation Factor-6 on the Intervertebral Disc: An In Vitro and In Vivo Study. Cells 2022,
11, 1174. [CrossRef]
Osada, R.; Ohshima, H.; Ishihara, H.; Yudoh, K.; Sakai, K.; Matsui, H.; Tsuji, H. Autocrine/paracrine mechanism of insulin-like
growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs.
J. Orthop. Res. 1996, 14, 690–699. [CrossRef]
Shinmei, M.; Masuda, K.; Kikuchi, T.; Shimomura, Y. The role of cytokines in chondrocyte mediated cartilage degradation.
J. Rheumatol. Suppl. 1989, 18, 32–34.
Pulai, J.I.; Chen, H.; Im, H.J.; Kumar, S.; Hanning, C.; Hegde, P.S.; Loeser, R.F. NF-kappa B mediates the stimulation of cytokine
and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J. Immunol. 2005, 174, 5781–5788.
[CrossRef] [PubMed]
Kato, K.; Akeda, K.; Miyazaki, S.; Yamada, J.; Muehleman, C.; Miyamoto, K.; Asanuma, Y.A.; Asanuma, K.; Fujiwara, T.;
Lenz, M.E.; et al. NF-kB decoy oligodeoxynucleotide preserves disc height in a rabbit anular-puncture model and reduces pain
induction in a rat xenograft-radiculopathy model. Eur. Cells Mater. 2021, 42, 90–109. [CrossRef] [PubMed]
Aida, Y.; Maeno, M.; Ito-Kato, E.; Suzuki, N.; Shiratsuchi, H.; Matsumura, H. Effect of IL-1alpha on the expression of cartilage
matrix proteins in human chondrosarcoma cell line OUMS-27. Life Sci. 2004, 75, 3173–3184. [CrossRef] [PubMed]
Thompson, J.P.; Oegema, T.R., Jr.; Bradford, D.S. Stimulation of mature canine intervertebral disc by growth factors. Spine 1991,
16, 253–260. [CrossRef]
Burke, J.G.; Watson, R.W.G.; Conhyea, D.; McCormack, D.; Dowling, F.E.; Walsh, M.G.; Fitzpatrick, J.M. Human nucleus pulposis
can respond to a pro-inflammatory stimulus. Spine 2003, 28, 2685–2693. [CrossRef]
Le Maitre, C.L.; Hoyland, J.A.; Freemont, A.J. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits
matrix degradation in the intact degenerate human intervertebral disc: An in situ zymographic and gene therapy study.
Arthritis Res. Ther. 2007, 9, R83. [CrossRef] [PubMed]
Le Maitre, C.L.; Freemont, A.J.; Hoyland, J.A. The role of interleukin-1 in the pathogenesis of human intervertebral disc
degeneration. Arthritis Res. Ther. 2005, 7, R732–R745. [CrossRef]
Seguin, C.A.; Pilliar, R.M.; Roughley, P.J.; Kandel, R.A. Tumor necrosis factor-alpha modulates matrix production and catabolism
in nucleus pulposus tissue. Spine 2005, 30, 1940–1948. [CrossRef] [PubMed]
Ghivizzani, S.C.; Kang, R.; Georgescu, H.I.; Lechman, E.R.; Jaffurs, D.; Engle, J.M.; Watkins, S.C.; Tindal, M.H.; Suchanek, M.K.;
McKenzie, L.R.; et al. Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium
produces all major pathologies of human rheumatoid arthritis. J. Immunol. 1997, 159, 3604–3612. [CrossRef]
Luoma, K.; Riihimaki, H.; Luukkonen, R.; Raininko, R.; Viikari-Juntura, E.; Lamminen, A. Low back pain in relation to lumbar
disc degeneration. Spine 2000, 25, 487–492. [CrossRef]
Doita, M.; Kanatani, T.; Harada, T.; Mizuno, K. Immunohistologic study of the ruptured intervertebral disc of the lumbar spine.
Spine 1996, 21, 235–241. [CrossRef] [PubMed]
Shinmei, M.; Kikuchi, T.; Yamagishi, M.; Shimomura, Y. The role of interleukin-1 on proteoglycan metabolism of rabbit annulus
fibrosus cells cultured in vitro. Spine 1988, 13, 1284–1290. [CrossRef] [PubMed]
Le Maitre, C.L.; Freemont, A.J.; Hoyland, J.A. A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition
of intervertebral disc degeneration. Int. J. Exp. Pathol. 2006, 87, 17–28. [CrossRef] [PubMed]
Hosaka, K.; Ryu, J.; Saitoh, S.; Ishii, T.; Kuroda, K.; Shimizu, K. The combined effects of anti-TNFalpha antibody and IL-1 receptor
antagonist in human rheumatoid arthritis synovial membrane. Cytokine 2005, 32, 263–269. [CrossRef]
Kobayashi, M.; Squires, G.R.; Mousa, A.; Tanzer, M.; Zukor, D.J.; Antoniou, J.; Feige, U.; Poole, A.R. Role of interleukin-1 and
tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum. 2005, 52, 128–135. [CrossRef]
Nixon, R.; Bansback, N.; Brennan, A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with
rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology 2007, 46, 1140–1147. [CrossRef]
Int. J. Mol. Sci. 2023, 24, 12336
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
13 of 13
Horai, R.; Asano, M.; Sudo, K.; Kanuka, H.; Suzuki, M.; Nishihara, M.; Takahashi, M.; Iwakura, Y. Production of mice deficient
in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in
turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 1998, 187, 1463–1475. [CrossRef]
Clements, K.M.; Price, J.S.; Chambers, M.G.; Visco, D.M.; Poole, A.R.; Mason, R.M. Gene deletion of either interleukin-1beta,
interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee
osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum.
2003, 48, 3452–3463.
Geng, Y.; Valbracht, J.; Lotz, M. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase
and p38 by IL-1 and TNF in human articular chondrocytes. J. Clin. Investig. 1996, 98, 2425–2430. [CrossRef]
Fukui, N.; Zhu, Y.; Maloney, W.J.; Clohisy, J.; Sandell, L.J. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1
and TNF-alpha in normal and osteoarthritic chondrocytes. J. Bone Jt. Surg. Am. 2003, 85-A (Suppl. S3), 59–66. [CrossRef]
Studer, R.K.; Gilbertson, L.G.; Georgescu, H.; Sowa, G.; Vo, N.; Kang, J.D. p38 MAPK inhibition modulates rabbit nucleus
pulposus cell response to IL-1. J. Orthop. Res. 2008, 26, 991–998. [CrossRef]
Ulfgren, A.K.; Andersson, U.; Engstrom, M.; Klareskog, L.; Maini, R.N.; Taylor, P.C. Systemic anti-tumor necrosis factor alpha
therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 2000, 43,
2391–2396. [CrossRef] [PubMed]
Williams, R.O.; Feldmann, M.; Maini, R.N. Cartilage destruction and bone erosion in arthritis: The role of tumour necrosis factor
alpha. Ann. Rheum. Dis. 2000, 59 (Suppl. S1), i75–i80. [CrossRef] [PubMed]
Hanauer, L.B. Comment on prescribing tumor necrosis factor inhibitors. Arthritis Rheum. 2002, 47, 347–348. [CrossRef]
Klareskog, L.; Catrina, A.I.; Paget, S. Rheumatoid arthritis. Lancet 2009, 373, 659–672. [CrossRef] [PubMed]
Thompson, J.P.; Pearce, R.H.; Schechter, M.T.; Adams, M.E.; Tsang, I.K.; Bishop, P.B. Preliminary evaluation of a scheme for
grading the gross morphology of the human intervertebral disc. Spine 1990, 15, 411–415. [CrossRef]
Masuda, K.; Takegami, K.; An, H.; Kumano, F.; Chiba, K.; Andersson, G.B.J.; Schmid, T.; Thonar, E. Recombinant osteogenic
protein-1 upregulates extracellular matrix metabolism by rabbit annulus fibrosus and nucleus pulposus cells cultured in alginate
beads. J. Orthop. Res. 2003, 21, 922–930. [CrossRef]
Chiba, K.; Andersson, G.B.; Masuda, K.; Thonar, E.J. Metabolism of the extracellular matrix formed by intervertebral disc cells
cultured in alginate. Spine 1997, 22, 2885–2893. [CrossRef]
Mok, S.S.; Masuda, K.; Hauselmann, H.J.; Aydelotte, M.B.; Thonar, E.J. Aggrecan synthesized by mature bovine chondrocytes
suspended in alginate. Identification of two distinct metabolic matrix pools. J. Biol. Chem. 1994, 269, 33021–33027. [CrossRef]
Koyano, Y.; Hammerle, H.; Mollenhauer, J. Analysis of 3H-proline-labeled protein by rapid filtration in multiwell plates for the
study of collagen metabolism. Biotechniques 1997, 22, 706–708.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
...
論文の公開元へ
